Robert B. Geller - 01 Feb 2023 Form 4 Insider Report for Aravive, Inc.

Role
Chief Medical Officer
Signature
/s/ Abel Svitavsky, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 15:24:35 UTC
Previous filing
05 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARAV Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 01 Feb 2023 Common Stock 400,000 $1.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options vest over three years with 50% vesting on the one-year anniversary of the date of grant and the remaining 50% vesting on a pro rata basis on a monthly basis over a two-year period commencing on the month following the one-year anniversary of the grant date.